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surgeries per 1m of population in Poland, while the mean CSR in the European
Union in 2008 was 7.6k. The number of ophthalmologists in Poland is 10 times
higher than in India, while the CSR is lower by 25%. The average percentage of
day-case cataract surgeries in OECD countries is 85%, and in Poland this number is
as low as 15%. CONCLUSIONS: Poland is a country with poor, ineffective organiza-
tion of cataract surgeries and has one of the worst access to these procedures in
Europe. Actions aimed at improvement of access must be undertaken, otherwise
the situation will rapidly deteriorate due to aging of population.
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OBJECTIVES: Home dialysis is associated with significant benefits for patients
and health care systems, but its usage varies greatly across Europe. Population
characteristics (especially age) are often proposed as an explanation of this
variation. The aim of this analysis was to estimate the number of potential
peritoneal dialysis (PD) patients based on the current age distribution of end
stage renal disease (ESRD) patients in 14 European countries and the highest
usage of PD per age group among these countries (assuming health status per
age groups is similar across countries). METHODS: The age distribution of ESRD
patients and PD usage per age group were extracted from the 2009 European
Renal Association – European Dialysis and Transplant Association registry re-
port. The highest PD usage values in each age group of incident and prevalent
patients were applied to the overall age distribution of ESRD patients in the 14
countries to obtain an estimate of the potential number of PD patients. Differ-
ences with the current 2009 numbers were computed. RESULTS: Overall in 2009,
there were 5005 incident PD patients (15.8% of ESRD, 16.5% of dialysis patients) and
17175 prevalent patients (7.2% of ESRD, 12.2% of dialysis patients). The highest
proportion of PD patients in the 20-44, 45-64, 65-74, and 75  age groups were
respectively 55%, 39%, 34% and 32% of incident and 11%, 14%, 17% and 26% of
prevalent ESRD patients. Applying the highest proportions to the current age dis-
tribution of ESRD patients showed that an additional 6764 incident and 22272 ad-
ditional prevalent ESRD patients could potentially be treated at home with PD.
CONCLUSIONS: This analysis shows that in the group of 14 countries studied,
provided health status per age group is similar across countries, several thousand
more ESRD patients could be treated at home and benefit from the flexibility and
autonomy of such treatment.
PODIUM SESSION II:
RESEARCH ON THE USE OF UTILITIES
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OBJECTIVES: Currently, quality of life (QOL) utilities can be derived from both
generic QOL questionnaires and disease-specific questionnaires. The cancer-spe-
cific questionnaire QLQ-C30 has been mapped onto the EQ5D and has been valued
in a time-trade-off (TTO) study. The aim of this study was to compare utilities from
the EQ5D-5L with the utilities from the QLQ-C30 in acute leukemia patients.
METHODS: Analyses were performed on cross-sectional data collected from 86
acute leukemia patients who completed both EQ5D-5L and QLQ-C30. The cross-
walk value set was used to calculate EQ5D-5L utilities. The descriptive systems and
utility scores of the EQ5D-5L and QLQ-C30 were compared by evaluating mean and
median scores, range, floor and ceiling effects, correlations between utilities and
the ability to discriminate between patients who were able/unable to work.
RESULTS: Mean utility scores were 0.82, 0.82 and 0.85 for the EQ5D-5L, QLQ-C30-
mapping and QLQ-C30-TTO, respectively. The QLQ-C30-TTO utility score was sig-
nificantly higher than the other two utility scores. Utility scores ranged from 0.21-
1.0 for the EQ5D-5L and QLQ-C30-mapping and from 0.51-1.0 for the QLQ-C30-TTO.
The percentage of patients with a utility score of 1 was significantly higher with the
EQ5D-5L than with the QLQ-C30. Both the QLQ-C30 and the EQ5D-5L were able to
discriminate between patients who were able/unable to work.CONCLUSIONS:QOL
utilities for acute leukemia can adequately be calculated from both QLQ-C30-map-
ping and EQ5D-5L. In future studies, choice of QOL questionnaire should depend
upon the expected differences in health between interventions because mild
health problems are better detected by the QLQ-C30.
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OBJECTIVES: In many countries, utility measures are required for allocation deci-
sions. Unlike the EQ-5D (EuroQoL-5D), the DLQI (Dermatology Life Quality Index)
has not been developed for the derivation of utilities. Purpose of this study was to
develop and test an algorithm for the transformation of DLQI scores into EQ-5D
utility scores. METHODS: Pre-existing data of two cross-sectional studies (for de-
velopment, n  1,511; for cross-validation n  2,009) of German psoriasis patients
were reanalyzed. Both EQ-5D global score and EQ-5D visual analogue scale (VAS)
were used as utility measures. Correlations were computed to identify predictors of
EQ-5D utility scores. Linear stepwise regressions were conducted using DLQI and
further potential predictors to find the optimal mapping algorithm. RESULTS: Us-
ing only DLQI as predictor resulted in coefficients of determination of R2  0.235
(EQ-5D global score) and R2  0.242 (EQ-5D VAS). In the final algorithm, seven
predictors were included which correctly predicted EQ-5D VAS for 60.4% (develop-
ment database) and 60.8% of all patients (cross-validation database) within a range
of 15 units. The algorithm explained 31.3% of the EQ-5D variance in the develop-
ment database and 26.8% in the cross-validation database. CONCLUSIONS: In spite
of the wide definition of correct prediction (15 units), utility scores of less than
two thirds of the patients were predicted correctly. As opposed to the authors of
two publications on earlier mapping approaches, we therefore conclude that map-
ping of DLQI on EQ-5D in psoriasis patients has considerable limitations in validity
and clinical relevance.
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OBJECTIVES: To help facilitate economic evaluations of interventions for treating
cancer, we estimated utility indices for the frequently used cancer-specific instru-
ment of quality of life, by mapping it onto each of the HUI-2 and HUI-3 general
health preference-based indices. METHODS: A sample of 367 cancer patients from
the Vancouver Cancer Centre completed the FACT-G, HUI-2 and HUI-3 health-
related quality of life questionnaires. Models of the relationships between the
FACT-G and each of the preference based indices were estimated using regression
analyses. We examined three alternative modeling approaches: ordinary-least-
squares (OLS); generalized-linear-modeling (GLM) using a Gaussian distribution
and log link; and censored-least-absolute deviations (CLAD). The performance of
the models was assessed in terms of how well the responses to the cancer-specific
instrument predicted utilities from each of the preference-based instruments us-
ing the mean absolute error (MAE) and root mean square error (RMSE). We adjusted
for the socio-demographic and clinical characteristics of patients. RESULTS: Re-
sults from the final models of the three approaches did not differ significantly.
Physical, functional and emotional subscales of the FACT-G were significant pre-
dictors of the HUI-2 and HUI-3 utility scores. The root mean square error for the
HUI-3 was lower, suggesting better predictions than for the HUI-2. The OLS/GLM
predicted HUI-2 and HUI-3 scores matched the observed values more closely than
the CLAD. CONCLUSIONS: There is potential to estimate both HUI-2/HUI-3 utilities
using responses from the FACT-G cancer-specific measure of quality-of-life, even
though it was not designed as a utility instrument. Our results suggest that it is
possible to estimate Quality-Adjusted-Life-Years from studies where only cancer-
specific instruments have been administered.
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OBJECTIVES: The Health Utilities Index-Mark 2 (HUI-2) is a generic preference-
based assessment for measuring general health status. The aim is to describe
HUI-2 utility data from a European, phase 3 clinical trial of the prodrug stimulant
lisdexamfetamine dimesylate (LDX) in children and adolescents with attention-
deficit/hyperactivity disorder (ADHD). METHODS: A 7-week, randomized, double-
blind, placebo-controlled trial of an optimized once-daily dose of LDX (30mg, 50mg,
70mg) was conducted in patients (6–17 years) with ADHD. Osmotic release oral
system methylphenidate (OROS-MPH) was included as a reference arm. HUI-2 was
administered by the parent at baseline (day 0), visit 4 (day 28) and visit 7 (day 49). A
multi-attribute utility function based on the 15 health status questions of HUI-2
was determined for treatment responders and non-responders, when response
was defined as a clinical global impressions-improvement (CGI-I) score of 1 or 2, a
reduction from baseline in ADHD-rating scale (ADHD-RS) score of 25% or a
reduction from baseline in ADHD-RS score 30%. Endpoint was defined as the
last on-treatment visit at which a valid HUI-2 score was obtained. RESULTS: Of 336
randomized patients, 317 were included in the full analysis set (LDX, n104; pla-
cebo, n106; OROS-MPH, n107) and 196 patients completed the study. At end-
point and across all treatment groups, HUI-2 utility scores were higher for respond-
ers than non-responders when response was based on a CGI-I score 1 or 2 (0.895
[0.099], n287 vs 0.839 [0.142], n169), a reduction from baseline in ADHD-RS score
of25% (0.899 [0.097], n338 vs 0.809 [0.147], n115) or a reduction from baseline
in ADHD-RS score of 30% (0.902 [0.094], n322 vs 0.814 [0.148], n131).
CONCLUSIONS: In this short-term trial of LDX in children and adolescents with
ADHD, symptomatic response was reflected in better utility scores than non-re-
sponse. Supported by funding from Shire Development LLC.
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